Skip to main content
SpringerLink
Log in

Gesamtmortalitätsrisiko bei Typ-2-Diabetikern

Metformin vs. Monotherapie mit Glibenclamid, Glimiperid oder Glipizid

Overall mortality risk in patients with type 2 diabetes

Metformin versus monotherapy with glyburide, glimeperide or glipizide

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Horsdal HT, Johnsen SP, Sondergaard F et al (2009) Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 25:515–522

    Article  PubMed  CAS  Google Scholar 

  2. Khalangot M, Tronko M, Kravchenko V, Kovtun V (2009) Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 86:247–253

    Article  PubMed  CAS  Google Scholar 

  3. Pantalone KM, Kattan MW, Yu C et al (2010) The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 33:1224–1229

    Article  PubMed  CAS  Google Scholar 

  4. Zeller M, Danchin N, Simon D et al (2010) Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 95:4993–5002

    Article  PubMed  CAS  Google Scholar 

  5. Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908

    Article  PubMed  CAS  Google Scholar 

  6. Andersson C, Gislason GH, Jorgensen CH et al (2011) Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 94:119–125

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. GK Havelhöhe, Kladoweer Damm 221, 14089, Berlin, Deutschland

    M. Jecht

Authors
  1. M. Jecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Jecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jecht, M. Gesamtmortalitätsrisiko bei Typ-2-Diabetikern. Diabetologe 8, 490–491 (2012). https://doi.org/10.1007/s11428-012-0961-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-012-0961-7

Search

Navigation